Conlan, Maureen G.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 777

Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors

FOLSOM, A., WU, K., DAVIS, C., CONLAN, M., SORLIE, P., & SZKLO, M. (1991) · Atherosclerosis

Blood properties and coagulationBlood Coagulation and Thrombosis Mechanisms

Cited by 321